¼¼°èÀÇ µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå : µ¿¹° À¯Çüº°, Á¦Ç°º°, Åõ¿© °æ·Îº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¿¹Ãø(-2030³â)
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
»óǰÄÚµå : 1819102
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 254 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,014,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,423,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,549,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,171,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå ±Ô¸ð´Â 2025³â 17¾ï ´Þ·¯¿¡¼­ 2030³â¿¡´Â 30¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, CAGRÀº 12.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¹Ý·Áµ¿¹° Àα¸ÀÇ Áõ°¡¿Í ¹Ý·Áµ¿¹° ¾çÀ°·üÀÇ »ó½Â¿¡ ÈûÀÔ¾î °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼öÀÇÇÐÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× µ¿¹°º¸È£´Üü´Â µ¿¹°º¸È£ Ä·ÆäÀÎÀ» Àû±ØÀûÀ¸·Î ÃßÁøÇϰí ÀÖÀ¸¸ç, ¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ ÇǺÎÁúȯÀ» Á¶±â¿¡ Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖµµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2023-2030³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2025-2030³â
°ËÅä ´ÜÀ§ ±Ý¾×(100¸¸ ´Þ·¯/10¾ï ´Þ·¯)
ºÎ¹® µ¿¹° À¯Çüº°, Á¦Ç°º°, Åõ¿© °æ·Îº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

ÇÏÁö¸¸ ¹Ý·Áµ¿¹° ÀÇ·áºñ »ó½ÂÀ¸·Î ÀÎÇØ Ä¡·á µµÀÔÀÌ Á¦ÇѵǴ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ÁöħÀÌ ¾ö°ÝÇϰí ÀǾàǰ ½ÂÀο¡ ½Ã°£ÀÌ ¿À·¡ °É¸®±â ¶§¹®¿¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ¾ïÁ¦Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¹°¿¡µµ ºÒ±¸Çϰí, ÇǺΰú¿Í °ñ°üÀý¿° ÀÌ¿ÜÀÇ Ä¡·á ÀûÀÀÁõ È®´ë´Â »õ·Î¿î ½ÃÀå ±âȸ¸¦ Áö¼ÓÀûÀ¸·Î âÃâÇϰí ÀÖ½À´Ï´Ù.

Veterinary Monoclonal Antibodies Market-IMG1

¹Ý·Á°ß »çÀ°·ü Áõ°¡¿Í µ¿¹° °Ç°­ °ü¸®¿¡ ´ëÇÑ ÁöÃâ Áõ°¡·Î ÀÎÇØ °³ ºÎ¹®ÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. °³´Â ¾Ë·¹¸£±â, °õÆÎÀÌ °¨¿°, ¿ÜºÎ ±â»ýÃæ °¨¿° µî ÇǺΠÁúȯ¿¡ °É¸®±â ½¬¿ö ÀæÀº ÇǺΰú Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ Àΰ£È­ Ãß¼¼¿Í °í±Þ ¼öÀÇÇп¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¹°ÇÐÀû Á¦Á¦ ¹× Ç¥Àû ´ÜŬ·ÐÇ×ü Ä¡·á¸¦ Æ÷ÇÔÇÑ ÇǺΰú Ä¡·áÀÇ ¹ßÀüÀº ¹Ý·Á°ßÀÇ Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÌ ºÎ¹®¿¡¼­ ½ÃÀå¿¡¼­ÀÇ ¿ìÀ§¸¦ È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

ÇÇÇÏ Åõ¿© ºÎ¹®Àº Åõ¿©°¡ ¿ëÀÌÇÏ°í ¹Ý·Áµ¿¹°ÀÇ ¼øÀÀµµ°¡ ³ô±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿Ü¿ëÁ¦º¸´Ù Àü½Å¿ä¹ýÀ» ±ÇÀåÇÏ´Â ¼öÀǻ簡 Áõ°¡Çϰí, °¨¿°ÁõÀ» Ÿ°ÙÀ¸·Î ÇÑ »õ·Î¿î ´ÜŬ·ÐÇ×ü °³¹ßÀÌ ÁøÇàµÇ¸é¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¨¿°¼º ÁúȯÀ» Ÿ°ÙÀ¸·Î ÇÑ ´ÜŬ·ÐÇ×üÀÇ ±â¼ú Çõ½ÅÀº µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

»çÀÌÆ®Æ÷ÀÎÆ® ºÐ¾ß´Â °³ ¾ÆÅäÇÇ ÇǺο° Ä¡·á¸¦ À§ÇÑ ÃÖÃÊÀÌÀÚ À¯ÀÏÇÑ FDA ¹× EMA ½ÂÀÎ ´ÜŬ·ÐÇ×ü Ä¡·áÁ¦·Î¼­ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Á°ß ¾ÆÅäÇÇ ÇǺο°ÀÇ ³ôÀº À¯º´·ü, ÀÔÁõµÈ È¿°ú, ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ¼öÀÇ»ç ä¿ë·ü Áõ°¡·Î ÀÎÇØ »çÀÌÆ®Æ÷ÀÎÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °í±Þ ¼öÀÇÇÐ Ä¡·á¿¡ ´ëÇÑ º¸È£ÀÚµéÀÇ ÅõÀÚ ÀÇÁö°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

°³ ¾ÆÅäÇÇ ÇǺο°°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ÇǺΰú ºÐ¾ß°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ Á¶¿¡Æ¼½º(Zoetis)ÀÇ »çÀÌÅäÆ÷ÀÎÆ®(Cytopoint)¿Í °°Àº ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¹Ý·Á°ßÀÇ ¾Ë·¹¸£±â¼º ÇǺο° ¹× ¾ÆÅäÇǼº ÇǺο° Ä¡·á¿¡ ÀÖ¾î Àå±âÀûÀÎ ¿ÏÈ­¿Í ÃÖ¼ÒÇÑÀÇ ºÎÀÛ¿ëÀ¸·Î Å« ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ °Ç°­°ü¸®¿¡ ´ëÇÑ ÁöÃâ ÀÇÁö°¡ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

µ¿¹°º´¿ø/Àü¹®¼¾ÅÍ´Â µ¿¹°º´¿ø ¹æ¹® Áõ°¡¿Í ¹Ý·Áµ¿¹° °Ç°­°ü¸® Àü¹® ¼­ºñ½º ÀÌ¿ë °¡´É¼º¿¡ ÈûÀÔ¾î °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÌµé ½Ã¼³¿¡¼­´Â ´Ù¾çÇÑ Áõ»ó¿¡ ´ëÇÑ °í±Þ Áø´Ü, 󹿾à, ¼ö¼ú µî Á¾ÇÕÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇǺΰú Ä¡·á¿¡ ¹Ý·Áµ¿¹° º¸ÇèÀÌ Àû¿ëµÇ¸é¼­ º¸È£ÀÚµéÀÌ ¼öÀǻ翡°Ô Áø·á¸¦ ¹ÞÀ¸¸é¼­ ÀÌ ºÐ¾ßÀÇ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â Àß ±¸ÃàµÈ µ¿¹° °Ç°­ °ü¸® ÀÎÇÁ¶ó¿Í ³ôÀº ¹Ý·Áµ¿¹° »çÀ°·ü¿¡ ÈûÀÔ¾î 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ª¿¡´Â Çõ½ÅÀûÀÎ ´ÜŬ·ÐÇ×ü Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ´Â ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷µéÀÌ ¸¹ÀÌ ÁøÃâÇØ ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í µ¿¹° ÀÇ·á¿¡ ´ëÇÑ ÁöÃâÀÌ Áõ°¡ÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. °í±Þ ÆêÄɾî Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ¼¼°è µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå¿¡¼­ ºÏ¹ÌÀÇ ¿ìÀ§¸¦ ´õ¿í °­È­½Ã۰í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, µ¿¹° Á¾·ùº°, Á¦Ç°º°, Åõ¿© °æ·Îº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå(µ¿¹° À¯Çüº°)

Á¦7Àå µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå(Á¦Ç°º°)

Á¦8Àå µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå(Åõ¿© °æ·Îº°)

Á¦9Àå µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå(Ä¡·á ºÐ¾ßº°)

Á¦10Àå µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦11Àå µ¿¹°¿ë ´ÜŬ·ÐÇ×ü ½ÃÀå(Áö¿ªº°)

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global veterinary monoclonal antibodies market is projected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%. The market is experiencing significant growth, driven by the expanding companion animal population and rising pet ownership. Growing concerns about chronic diseases have further boosted the demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD million/billion)
SegmentsAnimal Type, Product, Therapy Area, Route of Administration, End user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa

However, the market faces challenges such as rising pet care costs, which can limit treatment adoption. Furthermore, strict regulatory guidelines and lengthy approval times for drugs further restrain market growth. Despite these hurdles, expanding therapeutic indications beyond dermatology and osteoarthritis continues to create new market opportunities.

Veterinary Monoclonal Antibodies Market - IMG1

"By animal type, the canine segment held the highest share in 2024."

The canine segment held the largest market share in 2024, driven by rising pet dog ownership and increasing spending on animal healthcare. Dogs are highly prone to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, which require frequent dermatological treatments. The growing trend of pet humanization and the demand for premium veterinary care further support market growth. Additionally, advancements in dermatological treatments, including biologics and targeted monoclonal antibody therapies, improve treatment outcomes for dogs, solidifying the segment's dominance in the market.

"By route of administration, the subcutaneous segment is projected to record the highest CAGR between 2025 and 2030."

The subcutaneous segment is expected to grow at the fastest rate during the forecast period due to its ease of administration and better pet owner compliance. Rising veterinary recommendations for systemic treatments over topical solutions and the ongoing development of new monoclonal antibodies targeting infectious diseases are increasing demand. Moreover, innovations in monoclonal antibodies targeting infectious diseases further support the segment's growth in the veterinary monoclonal antibodies market.

"By product, cytopoint was the leading segment in 2024."

The cytopoint segment held the largest market share in 2024, driven by its status as the first and only FDA- and EMA-approved monoclonal antibody therapy for treating canine atopic dermatitis. Additionally, the high prevalence of atopic dermatitis in dogs has increased demand for cytopoint due to its proven efficacy, safety profile, and rising adoption by veterinarians. The growing willingness of pet owners to invest in advanced veterinary treatments has further fueled market growth.

"By therapy type, dermatology surpassed other segments in 2024."

The dermatology segment held the largest market share in 2024 due to the rising prevalence of chronic diseases such as atopic dermatitis in dogs. Additionally, growing awareness of advanced treatment options like Cytopoint by Zoetis (US) has gained significant traction due to its long-lasting relief and minimal side effects in treating allergic and atopic dermatitis in dogs. The willingness to spend on pet healthcare has further driven this market growth.

"By end user, veterinary hospitals/specialty centers are expected to exhibit the fastest growth during the forecast period."

Veterinary hospitals/specialty centers are expected to grow at the fastest rate, fueled by the rise in veterinary visits and the availability of specialized pet healthcare services. These facilities offer comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical procedures for various conditions. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, boosting demand in this segment.

"North America accounted for the largest share in 2024."

North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in R&D for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, also drives market growth. The growing demand for premium pet care products further contributes to North America's dominance in the global veterinary monoclonal antibodies market.

A breakdown of the primary participants referred to for this report is provided below:

The major players operating in the veterinary monoclonal antibodies market are Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US).

Research Coverage

This report examines the veterinary monoclonal antibodies market based on animal type, product, therapy area, route of administration, end user, and region. It also considers factors such as drivers and restraints that influence market growth. The report highlights opportunities and challenges within the market and offers details about the competitive landscape for market leaders. Additionally, it analyzes micro markets concerning their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.

Reasons to Buy this Report

The report can assist both established firms and new or smaller companies in understanding the market dynamics, which can help them increase their market share. Companies purchasing the report may employ one or a combination of the five strategies listed below.

This report provides insights into the following points:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ANIMAL TYPE

7 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY PRODUCT

8 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION

9 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY THERAPY AREA

10 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER

11 VETERINARY MONOCLONAL ANTIBODIES MARKET, BY REGION

12 COMPETITIVE LANDSCAPE

13 COMPANY PROFILES

14 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â